Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Roche presents restistance-breaking antibiotic
Antibiotic resistance has become an urgent threat to global public health in recent decades....
Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
With the US$31m agreement Pierre Fabre licences the global rights to exarafenib and other pan-RAF program assets from Kinnate...
Roche jumps ship on AC Immune
In recent trials, both Semorinemab, a monoclonal antibody (mAb) binding all forms of Tau, and Crenezumab, a mAb targeting multiple forms of misfolded...
Swiss vaccine developer Limma Tech get CARB-X grant
LimmaTech said, it will use the grant to advance preclinical development of its hexavalent vaccine candidate targeting Neisseria gonorrheae. Using...
Roche leads Freenome Inc US$257m financing
Roche led the financing that will be used by San Francisco-based Freenome Inc to finance testing its early cancer detection platform in the Vallania...
German companies to revolutionise lab plastics market
Plastic consumables used in pharmaceutical and biotechnological research must meet high quality standards. A German start-up has now launched the...